699-P: Prerandomization Factors Associated with Time-in-Target Glucose Range with Hybrid Closed-Loop Use in a Six-Month Randomized Controlled Trial in Adults with Type 1 Diabetes

Background: In our published trial in 120 adults with type 1 diabetes (T1D), allocation to hybrid closed loop (HCL) increased Continuous Glucose Monitoring (CGM) Time in Range ((TIR), 70-180mg/dL) by 15 percentage points vs. user-determined insulin dosing. Recommended TIR is >70%. Objective: To e...

Full description

Saved in:
Bibliographic Details
Published inDiabetes (New York, N.Y.) Vol. 70; no. Supplement_1
Main Authors JENKINS, ALICIA, JANUSZEWSKI, ANDRZEJ S., KIRBY, ADRIENNE, MCAULEY, SYBIL A., LEE, MELISSA H., PALDUS, BARBORA, VOGRIN, SARA, BOCK, MARTIN DE, BURT, MORTON, COHEN, NEALE, COLMAN, PETER G., DAVIS, ELIZABETH A., HOLMES-WALKER, JANE, KEECH, ANTHONY C., MACISAAC, RICHARD, SIMS, CATRIONA M., SUNDARARAJAN, VIJAYA, TRAWLEY, STEVEN, WARD, GLENN M., JONES, TIM, O’NEAL, DAVID N.
Format Journal Article
LanguageEnglish
Published New York American Diabetes Association 01.06.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background: In our published trial in 120 adults with type 1 diabetes (T1D), allocation to hybrid closed loop (HCL) increased Continuous Glucose Monitoring (CGM) Time in Range ((TIR), 70-180mg/dL) by 15 percentage points vs. user-determined insulin dosing. Recommended TIR is >70%. Objective: To examine associations of pre-randomization factors with trial-end 3-weeks masked CGM TIR in adults with T1D treated with 6-months HCL. Methods: MDI and non-HCL pump users (no CGM) were randomized 1:1 to 26-weeks HCL (Medtronic 670G) or ongoing standard care. Analyses are on HCL group (n=55): Pre-randomization factors are related to trial-end masked CGM TIR >70 vs. ≤70% and to TIR as a continuous variable. Continuous variables are compared by t-test and binary variables by chi-square with significance at P<0.05. Results: Table: Pre-randomization characteristics by trial-end TIR > vs. ≤70%. Significant univariate correlations between trial-end TIR as a continuous variable existed for pre-randomization factors: HbA1c (at enrolment and randomization), 1,5-anhydroglucitol, CGM metrics: %TIR (70-180mg/dl), %TIR (70-140mg/dl), mean glucose, SD glucose. Conclusions: The main factor associated with HCL users achieving higher TIR was pre-randomization glycemia. TIR was not associated with age, sex, prior pump use and socioeconomic status.
ISSN:0012-1797
1939-327X
DOI:10.2337/db21-699-P